Fanny SOCKEEL MASSART

ArcaScience, a French AI Healthtech startup innovating benefit-risk evaluation to make better, safer drugs, has announced a €6 million Seed funding round to accelerate the clinical impact of its AI 🇫🇷 🏥 The round was led by The Moon Venture, with participation from Pleiade Venture, Plug and Play Tech Center, Bpifrance, and AKKA Technologies. “It takes 10+ years to bring a drug to market. There is a 90% fail rate and the average cost per drug that makes it to the market is $2.3 billion! Benefit-risk prediction is no longer a nice-to-have, but a prerequisite for building better drugs. This funding round will help us scale our product, and bring real benefit-risk clarity to both the pharma industry and patients,” said Romain CLEMENT, Founder and CEO at ArcaScience. Read here: https://lnkd.in/dW4cwvPa

71

10 commentaires

🚀 Last news, yes it is summer time and we still do deals ! We are excited to support deeptech innovation in healthcare. Better Angle is proud to join the €2.5M seed round of AUSTRAL Dx and Philippe Mendels-Flandre, alongside leading investors including SORBONNE VENTURE by AUDACIA, Aloe Private Equity, IXCORE GROUP, Kima Ventures, Super Capital, and several business angel networks (Capital Cell, Paris Business Angels, Angels Santé). Austral Dx is transforming cardio-pulmonary diagnostics with a non-contact, AI-powered medical device that delivers rapid and objective assessments in under two minutes. Their breakthrough ultrasound-based technology could reshape emergency care and help reduce ER overcrowding — a critical pain point with over 4 million annual visits related to respiratory distress or chest pain. We’re excited to back a visionary team addressing an urgent and global healthcare challenge. This is deeptech with real-world impact — and just the beginning. 👉 Learn more about their mission and technology, link in comment #HealthTech #Deeptech #CardioPulmonary #StartupInvestment #BetterAngle #MedicalInnovation #AIinHealthcare #AustralDx

67

4 commentaires

Feldhoff & Cie invests in Europe’s most promising female founders Yesterday, Auxxo announced the first closing of Auxxo Female Catalyst Fund II, raising €26 million to invest in early-stage European startups with female founding teams. We are proud to be part of this commitment to expanding access to capital and driving lasting change in the venture landscape. Congratulations to Bettine Schmitz, Dr. Gesa Miczaika, the whole Auxxo Female Catalyst Fund team and all fellow investors who share this vision. Excited to see what we can build together! 

195

23 commentaires

🎙️ Special IBC 2025 Episode – Retention Zone One of the most interesting conversations I had at IBC this year was with Gilles Domartini, CEO of Cleeng, right after the second edition of Retention Zone Live. We talked about how innovation in subscriptions is shifting — becoming more accessible and more intelligent. 👉 The big headline: Cleeng Pro. ➡️ A simplified way for any mid-sized publisher to launch a subscription service in under 60 minutes. ➡️ With just a few clicks you can create offers, set up a subscription page, consolidate app store data, and enable customer care. ➡️ And the real game changer? The first 10,000 monthly subscribers are free. ➡️ No contracts, no upfront cost — just the freedom to experiment, learn, and grow. For Vimeo users and smaller publishers frustrated by limited analytics, this could open entirely new doors. 👉 The second big announcement: ChurnIQ AI-ssistant. ➡️ Imagine a retention super-expert on demand. You ask: who’s at risk of churning, on which platform, and what’s the revenue impact? You get the answer instantly. ➡️ But more importantly, it doesn’t stop at insights. It suggests proven remedies, integrates with tools like Braze or Mailchimp, and can trigger campaigns automatically. It’s agentic AI in action — analytics flowing directly into decisions and execution. 📲 Finally, Gilles reminded me why we started Retention Zone in the first place: to create a space where the industry can share real challenges and shape better solutions together. That dialogue has already influenced Cleeng’s roadmap, and it shows the power of community in innovation. A guy with a scarf Benedicte Guichard Alexis Gaï Kirstin White Hjalmar Koedijker Joachim Bergman Kamila Palka Enzo Bermond Kübra Güven Chris Welsh #IBC2025 #RetentionZone #Subscriptions #AI #Streaming

37

3 commentaires

Can we predict a drug’s potential before it even reaches the market? And what if AI could restore fairness in clinical trials by bridging the best drug's potential with the right group of patients — faster? I had the pleasure of joining Ziryab DIDI on #LaCapsule to explore how AI can radically transform how we develop medicines. 🔹 90% of clinical trials fail. 🔹 Benefit-Risk analysis of drugs is 30 years late 🔹 Innovation must balance profitability with responsibility. At ArcaScience, we’ve built the most comprehensive benefit-risk database in the world — powered by 20+ AI models trained by clinicians, and already trusted by top-tier pharma. We help our partners anticipate therapeutic potential, reduce risk, and build drug profiles in seconds, not months. More than a tech shift, this is about responsibility: ✅ Making smarter decisions, ✅ Serving patients faster, ✅ And doing it transparently. Huge thanks to the podcast team for the thoughtful conversation, and to Clara Armand-Delille & Lucie Ramin for making this connection possible 🙏 🎧 Listen here: Spotify: https://lnkd.in/e4aptsfy YouTube: https://lnkd.in/e3UjfdAs Apple: https://lnkd.in/eJxHaqxr

41

9 commentaires